Brief: Better Therapeutics Announces New Data Highlighting Concurrent Use Of Aspyrerx And Glp-1 Receptor Agonists To Treat Type 2 Diabetes

Better Therapeutics

11/10/2023 12:59

Oct 11 (Reuters) - Better Therapeutics Inc  BTTX.O :
    * BETTER THERAPEUTICS ANNOUNCES NEW DATA HIGHLIGHTING
CONCURRENT
USE OF ASPYRERX AND GLP-1 RECEPTOR AGONISTS TO TREAT TYPE 2
DIABETES
    * BETTER THERAPEUTICS: TRIAL ESTABLISHED USE OF ASPYRERX
ALONGSIDE
STANDARD OF CARE SHOWING CLINICALLY MEANINGFUL, STATISTICALLY
SIGNIFICANT REDUCTION
    * BETTER THERAPEUTICS - ANALYSIS SHOWS ADJUNCTIVE USE OF
ASPYRERX
WITH STANDARD OF CARE LEADS TO SUBSTANTIALLY GREATER CLINICAL
IMPROVEMENT VERSUS CONTROL
    * BETTER THERAPEUTICS INC - PARTICIPANTS THAT WERE ON BOTH
GLP-1
MEDICATIONS AND ASPYRERX ALSO SHOWED GREATER HBA1C REDUCTION,
GREATER WEIGHT LOSS
    * BETTER THERAPEUTICS INC -  SUBGROUP ANALYSIS EXHIBITED AN
AVERAGE REDUCTION IN HBA1C OF 0.7% AT 90 DAYS, BETWEEN TWO
GROUPS

Source text for Eikon:  ID:nBw5QfkmFa 
Further company coverage:  BTTX.O 

 ((Reuters.Briefs@thomsonreuters.com))